

Contact:

Ron Holtz
Chief Financial Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte To Present at the 2006 Mid-Atlantic BIO Conference

Gaithersburg, MD, October 2, 2006 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale cell loading systems for cellular therapy, including personalized cellular approaches, announces Ron Holtz, Chief Financial Officer, will be presenting at the Mid-Atlantic BIO Conference at the Ronald Regan Building and International Trade Center, Washington, DC, on Tuesday, October 10th.

Mr. Holtz will provide a brief corporate overview and discuss enabling technology for therapeutic development and biotherapeutic manufacturing, collaborations with commercial partners, and the company's preclinical and clinical product candidates.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and several preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###